Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Neurofibromatosis 1 2Neurofibromatoses 2Neurofibroma, Plexiform 2Glioma 2Vascular Malformations 1Skin Diseases, Vascular 1Primary Malignant Peripheral Nerve Sheath Tumors 1Neurofibroma 1NF1 1Multiple Myeloma 1Lymphatic Abnormalities 1Lymphangioma, Cystic 1Lymphangioma 1Liposarcoma, Myxoid 1Liposarcoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Glioblastoma 1Central Nervous System Neoplasms 1Arteriovenous Malformations 1Advanced Solid Tumor 1

Interventions

tislelizumab 4pembrolizumab 4Injections 4toripalimab 3sotorasib 1serabelisib 1olaparib 1nedaplatin 1mirdametinib 1erdafitinib 1envafolimab 1darolutamide 1atezolizumab 1adagrasib 1abiraterone 1Taxes 1Nivolumab 1Magnetic Resonance Spectroscopy 1Fulvestrant 1Drug Therapy 1CD3 Complex 1Bevacizumab 1Antineoplastic Agents 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Solid Tumor × mirdametinib × 90 days × Clear all
NCT05580770 2026-05-01

Mirdametinib + BGB-3245 in Advanced Solid Tumors

SpringWorks Therapeutics, Inc.

Phase 1/2 Terminated
23 enrolled 22 charts
Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡